University of Texas: Locking Down Shape-Shifting Spike Protein Aids Development of COVID-19 Vaccine
August 06, 2020
August 06, 2020
AUSTIN, Texas, Aug. 6 -- The University of Texas issued the following news release on Aug. 5:
The experimental vaccine against SARS-CoV-2 that was the first to enter human trials in the United States has been shown to elicit neutralizing antibodies and a helpful T-cell response with the aid of a carefully engineered spike protein that mimics the infection-spreading part of the virus.
The latest paper about a Moderna-NIH vaccine that recently entered phase 3 human trials . . .
The experimental vaccine against SARS-CoV-2 that was the first to enter human trials in the United States has been shown to elicit neutralizing antibodies and a helpful T-cell response with the aid of a carefully engineered spike protein that mimics the infection-spreading part of the virus.
The latest paper about a Moderna-NIH vaccine that recently entered phase 3 human trials . . .